| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash | 7,329,298 | - | ||
| Prepaid expenses | 72,819 | 75,288 | ||
| Cash | - | 754,323 | ||
| Total current assets | 7,402,117 | 829,611 | ||
| Total assets | 7,402,117 | 829,611 | ||
| Trade accounts payable and accrued liabilities | 329,375 | 254,956 | ||
| Due to related parties | 93,432 | 93,432 | ||
| Preferred stock, no par value, 100,000,000 shares authorized and none issued or outstanding | - | 0 | ||
| Total current liabilities | 422,807 | 348,388 | ||
| Common stock, no par value 300,000,000 shares authorized, 30,514,304 and 29,762,671 shares issued and outstanding at june 30, 2025 and december 31, 2024, respectively | - | 0 | ||
| Total liabilities | 422,807 | 348,388 | ||
| Additional paid-in capital | 45,928,180 | 38,327,799 | ||
| Accumulated deficit | -38,948,870 | -37,846,576 | ||
| Total stockholders equity | 6,979,310 | 481,223 | ||
| Total liabilities and stockholders equity | 7,402,117 | 829,611 | ||
Telomir Pharmaceuticals, Inc. (TELO)
Telomir Pharmaceuticals, Inc. (TELO)